Evidence map›Paper›PMID 30237711›Full record

ArticleInternational journal of nanomedicine2018

Synthesis of multivalent polymer-aptamer conjugates with enhanced inhibitory potency.

Jacob T Martin, Marc Douaisi, Ammar Arsiwala, Manish Arha, Ravi S Kane

Open access · goldAbstract read
In one paragraph

Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Jacob T MartinKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Marc DouaisiCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.
Ammar ArsiwalaSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA, ravi.kane@chbe.gatech.edu.
Manish ArhaCenter for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY, USA.
Ravi S KaneSchool of Chemical & Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA, USA, ravi.kane@chbe.gatech.edu.
Georgia Institute of Technology · USRensselaer Polytechnic Institute · USMassachusetts Institute of Technology · US

Funding

Engineering Nanoscale Aptamer-based Biomaterials that Target Cellular ReceptorsR01EB015482 · NIBIB · RENSSELAER POLYTECHNIC INSTITUTE · PI KANE, RAVI S. · 2012 to 2015
$1.3M
NIBIB NIH HHS R01 EB015482
6 · The paper itself

Abstract

purposeWe are interested in designing a modular strategy for creating potent multivalent ligands, which frequently can be used as effective inhibitors of undesired biomolecular interactions. For example, such inhibitors might prevent the self-assembly of bacterial toxins or the attachment of a virus to its host cell receptors.

methodsWe used a biocompatible polyamino acid polymer as a scaffold for grafting multiple copies of an oligonucleotide aptamer (OA). Specifically, the carboxylates on the side chains of polyglutamic acid (PGA) were modified with a thiol-reactive linker,

resultsMultivalent PGA-OA conjugates with low, medium, and high valency were successfully prepared. The varying valency and successful purification to remove unconjugated OAs were confirmed by polyacrylamide gel electrophoresis. The resulting purified conjugates inhibited the binding of unconjugated monovalent OAs, and the measured half maximal inhibitory concentration (IC

conclusionMultivalent conjugation of OA ligands has potential as a generally useful way to improve the potency of the interaction between the ligand and its target receptor. We have demonstrated this principle with a known OA as a proof of concept as well a synthetic strategy that can be used to synthesize multivalent conjugates of other OAs.

Indexed as

Aptamers, NucleotideHumansLigandsOligonucleotidesPolyglutamic AcidPolymersAptamers, NucleotideLigandsOligonucleotidesPolyglutamic AcidPolymersgraftingoligonucleotidepolyglutamic acidpolyvalency

Identifiers

PMID30237711
PMCPMC6136935
OpenAlexW2890513430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.